Additionally, the clinical evaluation of 68Ga-FAPI-RGD, a PET probe simultaneously targeting fibroblast activation protein (FAP) and integrin αvβ3, has demonstrated higher tumor uptake and tumor-to-background ratio (TBR) compared to traditional 18F-FDG PET/CT. The gene discussed is FAP; the disease is neoplasm.